Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 45INDUSTRY 39NIH 6OTHER_GOV 1INDIV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Thymoma 1Sarcoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Neoplasm Metastasis 1Mesothelioma 1Lung Neoplasms 1Fallopian Tube Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

apatinib 3pembrolizumab 2Poly(ADP-ribose) Polymerase Inhibitors 2Hyperthermic Intraperitoneal Chemotherapy 2Bevacizumab 2taxane 1olaparib 1lenvatinib 1fludarabine 1cediranib 1Whole Genome Sequencing 1Valproic Acid 1Tranexamic Acid 1Tai Ji 1Surgical Procedures, Operative 1Sequence Analysis, RNA 1Saline Solution 1Radiation 1Qigong 1Propranolol 1Positron Emission Tomography Computed Tomography 1Population Groups 1Platinum 1Paclitaxel 1Neoadjuvant Therapy 1Interleukin-2 1Indocyanine Green 1Immunohistochemistry 1Hydralazine 1Gene Expression 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Ovarian Neoplasms × olaparib × Clear all
NCT05200260 2025-02-10

Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer

Shanghai Gynecologic Oncology Group

Phase 2 Recruiting
220 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡